Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

E. R. Petersen*, C. Ammitzbøll, H. B. Søndergaard, A. B. Oturai, P. S. Sørensen, A. C. Nilsson, L. Börnsen, M. von Essen, F. Sellebjerg

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

OriginalsprogEngelsk
Artikelnummer577085
TidsskriftJournal of Neuroimmunology
Vol/bind337
Antal sider8
ISSN0165-5728
DOI
StatusUdgivet - 15. dec. 2019

Fingeraftryk

CD146 Antigens
Activated-Leukocyte Cell Adhesion Molecule
Integrin alpha4beta1
Up-Regulation
Down-Regulation
Natalizumab

Citer dette

Petersen, E. R., Ammitzbøll, C., Søndergaard, H. B., Oturai, A. B., Sørensen, P. S., Nilsson, A. C., ... Sellebjerg, F. (2019). Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. Journal of Neuroimmunology, 337, [577085]. https://doi.org/10.1016/j.jneuroim.2019.577085
Petersen, E. R. ; Ammitzbøll, C. ; Søndergaard, H. B. ; Oturai, A. B. ; Sørensen, P. S. ; Nilsson, A. C. ; Börnsen, L. ; von Essen, M. ; Sellebjerg, F. / Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. I: Journal of Neuroimmunology. 2019 ; Bind 337.
@article{dc97076187914d7fb0b6207a9414c391,
title = "Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis",
abstract = "The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.",
keywords = "Adhesion molecules, ALCAM, Blood-brain barrier, MCAM-1, Multiple sclerosis, Natalizumab",
author = "Petersen, {E. R.} and C. Ammitzb{\o}ll and S{\o}ndergaard, {H. B.} and Oturai, {A. B.} and S{\o}rensen, {P. S.} and Nilsson, {A. C.} and L. B{\"o}rnsen and {von Essen}, M. and F. Sellebjerg",
year = "2019",
month = "12",
day = "15",
doi = "10.1016/j.jneuroim.2019.577085",
language = "English",
volume = "337",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

Petersen, ER, Ammitzbøll, C, Søndergaard, HB, Oturai, AB, Sørensen, PS, Nilsson, AC, Börnsen, L, von Essen, M & Sellebjerg, F 2019, 'Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis', Journal of Neuroimmunology, bind 337, 577085. https://doi.org/10.1016/j.jneuroim.2019.577085

Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis. / Petersen, E. R.; Ammitzbøll, C.; Søndergaard, H. B.; Oturai, A. B.; Sørensen, P. S.; Nilsson, A. C.; Börnsen, L.; von Essen, M.; Sellebjerg, F.

I: Journal of Neuroimmunology, Bind 337, 577085, 15.12.2019.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis

AU - Petersen, E. R.

AU - Ammitzbøll, C.

AU - Søndergaard, H. B.

AU - Oturai, A. B.

AU - Sørensen, P. S.

AU - Nilsson, A. C.

AU - Börnsen, L.

AU - von Essen, M.

AU - Sellebjerg, F.

PY - 2019/12/15

Y1 - 2019/12/15

N2 - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

AB - The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.

KW - Adhesion molecules

KW - ALCAM

KW - Blood-brain barrier

KW - MCAM-1

KW - Multiple sclerosis

KW - Natalizumab

U2 - 10.1016/j.jneuroim.2019.577085

DO - 10.1016/j.jneuroim.2019.577085

M3 - Journal article

VL - 337

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

M1 - 577085

ER -